Companies / BOC Sciences / Obinutuzumab
BOC Sciences

Obinutuzumab | BOC Sciences

Obinutuzumab is a humanized monoclonal antibody that inhibits CD20 for cancer therapy. In combination with chlorambucil, it was approved as a first-line treatment for chronic lymphocytic leukemia. It also can be used to treat follicular lymphoma.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.